nach oben

Erschienen in:

16.06.2017 | Review Article

The potential roles of bacteria to improve radiation treatment outcome

verfasst von: E. Kouhsari, A. Ghadimi-Daresajini, H. Abdollahi, N. Amirmozafari, S. R. Mahdavi, S. Abbasian, S. H. Mousavi, H. F. Yaseri, M. Moghaderi

Erschienen in: Clinical and Translational Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Many combined therapies have been proposed to enhance radiotherapy outcome, but they have several limitations. As a new feasible strategy, combination of radiotherapy with bacteria showed a significant positive impact on the tumor treatment and metastasis inhibition. Although probiotic bacteria and radiotherapy alone can be effective in the treatment of different cancers, the combination of these two therapies seems to enhance therapeutic outcome and is cost-effective. Bacterial cells can act as therapeutic/gene/drug delivery vehicles as well as theranostic agents. In this communication, we reviewed current evidences, studies, suggestions, and future-based directions on combination of radiotherapy and bacteria. In another sections, an overview on tumor hypoxia, bacteria in cancer therapy, and combination of radiotherapy and bacteria is presented. A brief overview on trials and animal studies which used bacteria to protect normal tissues against radiotherapy-induced complications is also included.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed

Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, Lievens Y, et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol. 2005;75(3):355–65.CrossRefPubMed

Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Tansl Med. 2013;5(173):1732sr2-sr2.

Datta N, Ordóñez SG, Gaipl U, Paulides M, Crezee H, Gellermann J, et al. Local hyperthermia combined with radiotherapy and-/or chemotherapy: recent advances and promises for the future. Cancer Treat Rev. 2015;41(9):742–53.CrossRefPubMed

Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol. 2004;49(18):N309.CrossRefPubMed

Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296(5577):2404–7.CrossRefPubMed

Higgins GS, O’Cathail SM, Muschel RJ, McKenna WG. Drug radiotherapy combinations: review of previous failures and reasons for future optimism. Cancer Treat Rev. 2015;41(2):105–13.CrossRefPubMed

Winczura P, Jassem J. Combined treatment with cytoprotective agents and radiotherapy. Cancer Treat Rev. 2010;36(3):268–75.CrossRefPubMed

10.

Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256–65.

11.

Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11(4):239–53.CrossRefPubMed

12.

Richardson RB, Harper M-E. Mitochondrial stress controls the radiosensitivity of the oxygen effect: implications for radiotherapy. Oncotarget. 2016;7(16):21469.CrossRefPubMedPubMedCentral

13.

Hill RP, Bristow RG, Fyles A, Koritzinsky M, Milosevic M, Wouters BG. Hypoxia and predicting radiation response. Semin Radiat Oncol. 2015;25(4):260–72.CrossRefPubMed

14.

Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M, Noman MZ. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol. 2012;3:21.CrossRefPubMedPubMedCentral

15.

Wang W-M, Zhao Z-L, Ma S-R, Yu G-T, Liu B, Zhang L, et al. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and notch1 in head neck squamous cell carcinoma. PLoS One. 2015;10(2):e0119723.CrossRefPubMedPubMedCentral

16.

Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47.CrossRefPubMed

17.

Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307.CrossRefPubMedPubMedCentral

18.

Feng H, Wang J, Chen W, Shan B, Guo Y, Xu J, et al. Hypoxia-induced autophagy as an additional mechanism in human osteosarcoma radioresistance. J Bone Oncol. 2016;5(2):67–73.CrossRefPubMedPubMedCentral

19.

Corry J, Rischin D. Strategies to overcome accelerated repopulation and hypoxia—What have we learned from clinical trials? Semin Oncol. 2004;31(6):802–8.CrossRefPubMed

20.

Peters LJ. Targeting hypoxia in head and neck cancer. Act Oncol. 2001;40(8):937–40.CrossRef

21.

Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007;26(2):241–8.CrossRefPubMed

22.

Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol. 1996;6(1):10–21.CrossRefPubMed

23.

Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med. 2009;9(4):442–58.CrossRefPubMedPubMedCentral

24.

Machtay M, Pajak TF, Suntharalingam M, Shenouda G, Hershock D, Stripp DC, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys. 2007;69(4):1008–17.CrossRefPubMed

25.

Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys. 2005;63(1):25–36.CrossRefPubMed

26.

Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol. 2007;19(6):397–417.CrossRef

27.

Denny WA, Wilson WR. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Exp Opin Invest Drugs. 2000;9(12):2889–901.CrossRef

28.

Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer. 2009;9(2):134–42.CrossRefPubMedPubMedCentral

29.

Rodemann HP, Blaese MA. Responses of normal cells to ionizing radiation. Semin Radiat Oncol. 2007;17(2):81–8.CrossRefPubMed

30.

Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27(3):247–54.CrossRefPubMed

31.

Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer. 2010;10(11):785–94.CrossRefPubMedPubMedCentral

32.

Patyar S, Joshi R, Byrav DP, Prakash A, Medhi B, Das B. Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci. 2010;17(1):21.CrossRefPubMedPubMedCentral

33.

Felgner S, Kocijancic D, Frahm M, Weiss S. Bacteria in cancer therapy: renaissance of an old concept. Int J Microbiol. 2016;8(45):17–28.

34.

Nallar SC, Xu D-Q, Kalvakolanu DV. Bacteria and genetically modified bacteria as cancer therapeutics: current advances and challenges. Cytokine. 2017;89:160–72.CrossRefPubMed

35.

Minton NP. Clostridia in cancer therapy. Nat Rev Microbiol. 2003;1(3):237–42.CrossRefPubMed

36.

Carswell E, Old LJ, Kassel R, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Nat Acad Sci. 1975;72(9):3666–70.CrossRefPubMedPubMedCentral

37.

Nougayrède J-P, Taieb F, De Rycke J, Oswald E. Cyclomodulins: bacterial effectors that modulate the eukaryotic cell cycle. Trend Microbiol. 2005;13(3):103–10.CrossRef

38.

Oswald E, Sugai M, Labigne A, Wu HC, Fiorentini C, Boquet P, et al. Cytotoxic necrotizing factor type 2 produced by virulent Escherichia coli modifies the small GTP-binding proteins Rho involved in assembly of actin stress fibers. Proc Nat Acad Sci. 1994;91(9):3814–8.CrossRefPubMedPubMedCentral

39.

Pastan I, FitzGerald D. Recombinant toxins for cancer treatment. Science. 1991;254(5035):1173.CrossRefPubMed

40.

Antignani A, FitzGerald D. Immunotoxins: the role of the toxin. Toxins. 2013;5(8):1486–502.CrossRefPubMedPubMedCentral

41.

Wei MQ, Ellem KA, Dunn P, West MJ, Bai CX, Vogelstein B. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur J Cancer. 2007;43(3):490–6.CrossRefPubMed

42.

Ryan RM, Green J, Lewis CE. Use of bacteria in anti-cancer therapies. BioEssays. 2006;28(1):84–94.CrossRefPubMed

43.

Van Mellaert L, Barbé S, Anné J. Clostridium spores as anti-tumour agents. Trend Microbiol. 2006;14(4):190–6.CrossRef

44.

Zhou S. Synthetic biology: bacteria synchronized for drug delivery. Nature. 2016;536(7614):33–4.CrossRefPubMed

45.

Fensterle J, Bergmann B, Yone C, Hotz C, Meyer S, Spreng S, et al. Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B. Cancer Gene Ther. 2008;15(2):85–93.CrossRefPubMed

46.

Zhao M, Yang M, Ma H, Li X, Tan X, Li S, et al. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res. 2006;66(15):7647–52.CrossRefPubMed

47.

Avogadri F, Martinoli C, Petrovska L, Chiodoni C, Transidico P, Bronte V, et al. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res. 2005;65(9):3920–7.CrossRefPubMed

48.

Frankel AE, Rossi P, Kuzel TM, Foss F. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr Cancer Drug Targets. 2002;2(1):19–36.CrossRefPubMed

49.

Hagihara N, Walbridge S, Olson AW, Oldfield EH, Youle RJ. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. Cancer Res. 2000;60(2):230–4.PubMed

50.

Xu J, Liu XS, Zhou S-F, Wei MQ. Combination of immunotherapy with anaerobic bacteria for immunogene therapy of solid tumours. Gene Ther Mol Biol. 2009;13:36–52.

51.

Sznol M, Lin SL, Bermudes D, Zheng L-M, King I. Use of preferentially replicating bacteria for the treatment of cancer. J Clin Invest. 2000;105(8):1027–30.CrossRefPubMedPubMedCentral

52.

Jain RK, Forbes NS. Can engineered bacteria help control cancer? Proc Nat Acad Sci. 2001;98(26):14748–50.CrossRefPubMedPubMedCentral

53.

Parvez S, Malik KA, Ah Kang S, Kim HY. Probiotics and their fermented food products are beneficial for health. J Appl Microbiol. 2006;100(6):1171–85.CrossRefPubMed

54.

Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr. 2001;73(2):451s–5s.PubMed

55.

Bettegowda C, Dang LH, Abrams R, Huso DL, Dillehay L, Cheong I, et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Nat Acad Sci. 2003;100(25):15083–8.CrossRefPubMedPubMedCentral

56.

Nuyts S, Van Mellaert L, Theys J, Landuyt W, Lambin P, Anné J. The use of radiation-induced bacterial promoters in anaerobic conditions: a means to control gene expression in clostridium-mediated therapy for cancer. Radiat Res. 2001;155(5):716–23.CrossRefPubMed

57.

Nuyts S, Van Mellaert L, Theys J, Landuyt W, Bosmans E, Anné J, et al. Radio-responsive recA promoter significantly increases TNF [alpha] production in recombinant clostridia after 2 Gy irradiation. Gene Ther. 2001;8(15):1197.CrossRefPubMed

58.

Jiang S-N, Phan TX, Nam T-K, Nguyen VH, Kim H-S, Bom H-S, et al. Inhibition of tumor growth and metastasis by a combination of Escherichia coli–mediated cytolytic therapy and radiotherapy. Mol Ther. 2010;18(3):635–42.CrossRefPubMedPubMedCentral

59.

Platt J, Sodi S, Kelley M, Rockwell S, Bermudes D, Low K, et al. Antitumour effects of genetically engineered Salmonella in combination with radiation. Euro J Cancer. 2000;36(18):2397–402.CrossRef

60.

Liu X, Jiang S, Piao L, Yuan F. Radiotherapy combined with an engineered Salmonella typhimurium inhibits tumor growth in a mouse model of colon cancer. Exp Anim. 2016;65(4):413–8.CrossRefPubMedPubMedCentral

61.

Abdollahi H. Beneficial effects of cellular autofluorescence following ionization radiation: hypothetical approaches for radiation protection and enhancing radiotherapy effectiveness. Med Hypotheses. 2015;84(3):194–8.CrossRefPubMed

62.

Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18(19):3339–45.CrossRefPubMed

63.

Abdollahi H. Probiotic-based protection of normal tissues during radiotherapy. Nutrition. 2014;30(4):495.CrossRefPubMed

64.

Khademi S, Abdollahi H. Application of hydrogen producing microorganisms in radiotherapy: an idea. Iran J Public Health. 2014;43:1018–9.PubMedPubMedCentral

65.

Abdollahi H, Shiri I, Atashzar M, Sarebani M, Moloudi K, Samadian H. Radiation protection and secondary cancer prevention using biological radioprotectors in radiotherapy. Int J Cancer Ther Oncol. 2015;3(3):1–9.

66.

Abdollahi H, Atashzar M, Amini M. The potential use of biogas producing microorganisms in radiation protection. J Med Hypotheses Ideas. 2015;9(2):67–71.CrossRef

67.

Group JFWW, Group JFWW. Guidelines for the evaluation of probiotics in food. London: World Health Organization, ON, Canada: Food and Agriculture Organization. 2002.

68.

Ciorba MA, Riehl TE, Rao MS, Moon C, Ee X, Nava GM, et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut. 2012;61(6):829–38.CrossRefPubMed

69.

Demirer S, Aydıntug S, Aslım B, Kepenekci I, Sengül N, Evirgen O, et al. Effects of probiotics on radiation-induced intestinal injury in rats. Nutrition. 2006;22(2):179–86.CrossRefPubMed

70.

Seal M, Naito Y, Barreto R, Lorenzetti A, Safran P, Marotta F. Experimental radiotherapy-induced enteritis: a probiotic interventional study. J Dig Dis. 2007;8(3):143–7.CrossRefPubMed

71.

Mego M, Holec V, Drgona L, Hainova K, Ciernikova S, Zajac V. Probiotic bacteria in cancer patients undergoing chemotherapy and radiation therapy. Complement Ther Med. 2013;21(6):712–23.CrossRefPubMed

72.

Delia P, Sansotta G, Donato V, Frosina P, Messina G, De Renzis C, et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol. 2007;13(6):912.CrossRefPubMedPubMedCentral

73.

Sharma A, Rath G, Chaudhary S, Thakar A, Mohanti BK, Bahadur S. Lactobacillus brevis CD2 lozenges reduce radiation-and chemotherapy-induced mucositis in patients with head and neck cancer: a randomized double-blind placebo-controlled study. Eur J Cancer. 2012;48(6):875–81.CrossRefPubMed

74.

Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. Clin Nutr. 2014;33(5):761–7.CrossRefPubMed

75.

Österlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007;97(8):1028–34.CrossRefPubMedPubMedCentral

76.

Giralt J, Regadera JP, Verges R, Romero J, de la Fuente I, Biete A, et al. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys. 2008;71(4):1213–9.CrossRefPubMed

77.

Delia P, Sansotta G, Donato V, Messina G, Frosina P, Pergolizzi S, et al. Prevention of radiation-induced diarrhea with the use of VSL# 3, a new high-potency probiotic preparation. Am J Gastroenterol. 2002;97(8):2150.CrossRefPubMed

78.

Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62(11):1064–79.CrossRefPubMedPubMedCentral

79.

Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62(11):1052–63.CrossRefPubMedPubMedCentral

80.

Chen F, Ehlerding EB, Cai W. Theranostic nanoparticles. J Nucl Med. 2014;55(12):1919–22.CrossRefPubMedPubMedCentral

81.

Miladi I, Alric C, Dufort S, Mowat P, Dutour A, Mandon C, et al. The in vivo radiosensitizing effect of gold nanoparticles based MRI contrast agents. Small. 2014;10(6):1116–24.CrossRefPubMed

82.

Detappe A, Lux F, Tillement O. Pushing radiation therapy limitations with theranostic nanoparticles. Nanomed. 2016;11(9):997–9.CrossRef

83.

Sancey L, Lux F, Kotb S, Roux S, Dufort S, Bianchi A, et al. The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy. Br J Radiol. 1041;2014(87):20140134.

84.

Park SJ, Park S-H, Cho S, Kim D-M, Lee Y, Ko SY, et al. New paradigm for tumor theranostic methodology using bacteria-based microrobot. Sci Rep. 2013;3:3394.CrossRefPubMedPubMedCentral

85.

Kojima R, Aubel D, Fussenegger M. Toward a world of theranostic medication: programming biological sentinel systems for therapeutic intervention. Adv Drug Deliv Rev. 2016;105:66–76.CrossRefPubMed

86.

Wu HC, Tsao CY, Quan DN, Cheng Y, Servinsky MD, Carter KK, et al. Autonomous bacterial localization and gene expression based on nearby cell receptor density. Mol Syst Biol. 2013;9(1):636.CrossRefPubMedPubMedCentral

87.

Quispe-Tintaya W, Chandra D, Jahangir A, Harris M, Casadevall A, Dadachova E, et al. Nontoxic radioactive Listeriaat is a highly effective therapy against metastatic pancreatic cancer. Proc Nat Acad Sci. 2013;110(21):8668–73.CrossRefPubMedPubMedCentral

88.

Luo C-H, Huang C-T, Su C-H, Yeh C-S. Bacteria-mediated hypoxia-specific delivery of nanoparticles for tumors imaging and therapy. Nano Lett. 2016;16(6):3493–9.CrossRefPubMed

89.

Martel S, Mohammadi M, Felfoul O, Lu Z, Pouponneau P. Flagellated magnetotactic bacteria as controlled MRI-trackable propulsion and steering systems for medical nanorobots operating in the human microvasculature. Int J Robot Res. 2009;28(4):571–82.CrossRef

90.

Zurkiya O, Chan AW, Hu X. MagA is sufficient for producing magnetic nanoparticles in mammalian cells, making it an MRI reporter. Mag Resonan Med. 2008;59(6):1225–31.CrossRef

91.

Pfeifer F. Distribution, formation and regulation of gas vesicles. Nat Rev Microbiol. 2012;10(10):705–15.CrossRefPubMed

92.

Oren A. The function of gas vesicles in halophilic archaea and bacteria: theories and experimental evidence. Life. 2012;3(1):1–20.CrossRefPubMedPubMedCentral

93.

Shapiro MG, Goodwill PW, Neogy A, Yin M, Foster FS, Schaffer DV, et al. Biogenic gas nanostructures as ultrasonic molecular reporters. Nat Nanotechnol. 2014;9(4):311–6.CrossRefPubMedPubMedCentral

94.

Ibsen S, Schutt CE, Esener S. Microbubble-mediated ultrasound therapy: a review of its potential in cancer treatment. Drug Des Dev Ther. 2013;7:375–88.CrossRef

95.

Kiessling F, Fokong S, Koczera P, Lederle W, Lammers T. Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics. J Nucl Med. 2012;53(3):345–8.CrossRefPubMed

96.

Wang X, Gkanatsas Y, Palasubramaniam J, Hohmann JD, Chen YC, Lim B, et al. Thrombus-targeted theranostic microbubbles: a new technology towards concurrent rapid ultrasound diagnosis and bleeding-free fibrinolytic treatment of thrombosis. Theranostics. 2016;6(5):726.CrossRefPubMedPubMedCentral

97.

Jibu T, Ando K, Matsumoto T, Koike S, Kobori O, Morioka Y, et al. Active components of intestinal bacteria for abdominal irradiation-induced inhibition of lung metastases. Clin Exp Metastasis. 1991;9(6):529–40.CrossRefPubMed

98.

Fang J, Liao L, Yin H, Nakamura H, Shin T, Maeda H. Enhanced bacterial tumor delivery by modulating the EPR effect and therapeutic potential of Lactobacillus casei. J Pharm Sci. 2014;103(10):3235–43.CrossRefPubMed

99.

Dietzel F, Gericke D, König W. Tumor hyperthermia using high frequency for increase of oncolysis by Clostridium butyricum (M 55). Strahlentherapie. 1976;152(6):537–41.PubMed

100.

Dietzel F, Gericke D. Intensification of the oncolysis by clostridia by means of radio-frequency hyperthermy in experiments on animals–dependence on dosage and on intervals (author’s transl). Strahlentherapie. 1977;153(4):263–6.PubMed

101.

Crawford PA, Gordon JI. Microbial regulation of intestinal radiosensitivity. Proc Nat Acad Sci USA. 2005;102(37):13254–9.CrossRefPubMedPubMedCentral

102.

Kainthola A, Gupta N, Agrawala PK. Gastrointestinal microflora in radiation injury and countermeasure. Ann Res Rev Biol. 2016;10(1):1–22.

103.

Liu Q, Nobaek S, Adawi D, Mao Y, Wang M, Molin G, et al. Administration of Lactobacillus plantarum 299v reduces side‐effects of external radiation on colon anastomotic healing in an experimental model. Colorectal Dis. 2001;3(4):245–52.

104.

Chitapanarux I, Chitapanarux T, Traisathit P, Kudumpee S, Tharavichitkul E, Lorvidhaya V. Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol. 2010;5(1):31.

105.

Tanaka I, Tanaka M, Satoh A, Kurematsu A, Ishiwata A, Suzuki K, et al. Alteration of radioprotective effects of heat-killed Lactobacillus casei in X-irradiated C3H/He mouse related to blood level of proinflammatory cytokines by corticoids. J Radiat Res. 2010;51(1):81–6.

106.

García-Peris P, Gimeno CV, Lozano M, Moreno Y, Paron L, de la Cuerda Compés C, et al. Effect of a mixture of inulin and fructo-oligosaccharide on lactobacillus and bifidobacterium intestinal microbiota of patients receiving radiotherapy; a randomised, double-blind, placebo-controlled trial. Nutr Hosp. 2012;27(6):1908–15.

107.

Ki Y, Kim W, Cho H, Ahn K, Choi Y, Kim D. The effect of probiotics for preventing radiation-induced morphological changes in intestinal mucosa of rats. J Korean Med Sci. 2014;29(10):1372–8.

108.

Nomoto K, Yokokura T, Tsuneoka K, Shikita M. Radioprotection of mice by a single subcutaneous injection of heat-killed Lactobacillus casei after irradiation. Radiation Res. 1991;125(3):293–7.

Titel: The potential roles of bacteria to improve radiation treatment outcome
verfasst von: E. Kouhsari
A. Ghadimi-Daresajini
H. Abdollahi
N. Amirmozafari
S. R. Mahdavi
S. Abbasian
S. H. Mousavi
H. F. Yaseri
M. Moghaderi
Publikationsdatum: 16.06.2017
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 2/2018
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1701-7

Springer Medizin

The potential roles of bacteria to improve radiation treatment outcome

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Histopathological factors predicting response to neoadjuvant therapy in gastric carcinoma

Management of unresectable, locally advanced pancreatic adenocarcinoma

Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan

An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis

Clinicopathologic parameters associated with postoperative complications and risk factors for tumor recurrence and mortality after tumor resection of patients with colorectal cancer

Quality of life after whole brain radiotherapy compared with radiosurgery of the tumor bed: results from a randomized trial

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie